Enozertinib's Phase 1b data position it as a potential best-in-class therapy for EGFR atypical NSCLC, with strong systemic and CNS activity and a clean safety profile. The upcoming Redwood-1 Phase 3 initiation in 1H 2027 is the key catalyst. Monitor for additional data from the Phase 1b exon 20 cohort and combination studies with amivantamab expected mid-2027.
Price Chart
Executive Summary
ORIC Pharmaceuticals presented updated Phase 1b data for enozertinib in 1L EGFR atypical NSCLC at ESMO 2026, showing an 84% confirmed systemic ORR, 70% CNS ORR, and 88% 6-month landmark PFS with no treatment-related discontinuations. The company also announced plans to initiate the Redwood-1 global Phase 3 registrational trial in 1H 2027 following End-of-Phase 1 FDA interactions.
Key Facts
- 84% confirmed systemic ORR by investigator and 80% by BICR in 1L EGFR atypical NSCLC (n=25 response-evaluable)
- 70% confirmed intracranial ORR by investigator; 67% by BICR RANO-BM with 40% complete response rate
- 88% Kaplan-Meier 6-month landmark PFS; median PFS and DOR data immature
- 65% of patients had baseline CNS metastases (more than double competitor datasets); 46% had previously untreated brain metastases
- No treatment-related discontinuations; no Grade 4/5 TRAEs; all Grade 3 TRAEs resolved with dose modifications
- 100% of evaluable patients achieved MR90 ctDNA reduction; 82% achieved full clearance
- Redwood-1 Phase 3 trial planned to initiate in 1H 2027, enrolling ~360 patients with dual primary endpoints of ORR and PFS by BICR
- End-of-Phase 1 FDA interactions completed with alignment on patient population and control arm
Financial Impact
1L EGFR Atypical NSCLC is a >$2.5 billion US market opportunity; total potential US commercial opportunity across both EGFR atypical and exon 20 is >$3.5 billion annually
Risk Factors
- Phase 3 data may not replicate Phase 1b results in a larger, randomized setting
- Competing therapies (amivantamab + lazertinib, firmonertinib) are also in development for this indication
- ORIC is a clinical-stage company with no approved products and will need additional capital to fund Phase 3 trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-429465 |
| Document: d152009d8k.htm | 0001193125-26-429465 |
| Document: 0001193125-26-429465-index-headers.html | 0001193125-26-429465 |
| Document: 0001193125-26-429465-index.html | 0001193125-26-429465 |
| Document: 0001193125-26-429465.txt | 0001193125-26-429465 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $13.17 $8.96 | ▼ −32.00% | ▼ −32.72% | $9.00 (−31.66%) |
Oct 5, 2026 22d ago | Press Release | $11.98 $12.01 | ▲ +0.25% | ▲ +0.49% | $9.00 (−24.87%) |
Oct 2, 2026 25d ago | Insider Cluster | $12.49 $11.98 | ▼ −4.08% | ▼ −4.63% | $9.00 (−27.94%) |
Aug 3, 2026 12w ago | Press Release | $13.47 $12.93 | ▼ −4.01% | ▼ −3.81% | $9.00 (−33.18%) |
Jun 22, 2026 18w ago | 8-K | $8.91 $9.43 | ▲ +5.84% | ▲ +5.88% | $9.00 (+1.01%) |
Jun 11, 2026 19w ago | Institutional Cluster | $7.82 $8.27 | ▲ +5.75% | ▲ +5.21% | $9.00 (+15.09%) |
May 4, 2026 25w ago | 8-K | $9.57 $9.57 | · 0.00% | ▼ −1.38% | $9.00 (−5.96%) |
Apr 3, 2026 29w ago | Press Release | $8.91 $8.87 | ▼ −0.45% | ▼ −0.51% | $9.00 (+1.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers